A clinical study about the value of cardiac myosin binding protein C tested by a high sensitivity method in the diagnosis and treatment of acute myocardial infarction

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200056973

Enrollment

Unknown

Registered

2022-02-25

Start date

2022-03-01

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction

Interventions

Gold Standard:POCT analyzer

Index test:High sensitive gold nanocage method

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients aged >= 18 years with acute chest discomfort; 2. Symptom onset or acute exacerbation time <= 12 hours.

Exclusion criteria

Exclusion criteria: 1. Patients with normal cTnI level were not excluded from AMI; 2. Patients with elevated cTnI level and uncertin final diagnosis; 3. Patients who failed to retain blood samples.

Design outcomes

Primary

Measure	Time frame
cardiac myosin binding protein C;	—

Secondary

Measure	Time frame
cardiac troponin I, cTnI;	—

Countries

China

Contacts

Public ContactYiyang Zhan

The First Affiliated Hospital of Nanjing Medical University

yiyangzhan@sina.com+86 18912972893

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026